Cancel
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals Employees
12 people indexed:
-
Daniel C. Martin
Senior Vice President, Chief Commercial Officer
00.0f5yfv@wx4xfwyl1.gv8 Sign up to see email8u.594970@30gy1sv4x.fgu Sign up to see email -
Dashyant Dhanak, Ph.D.
Executive Vice President, Chief Scientific Officer
f5tslgz.15.x@tuuq371z1.lw2 Sign up to see emailg301zsb.9q.x@bzv7t9wyt.f6f Sign up to see email -
Jama Pitman
Senior Vice President, Chief Development Officer
zss8gz3@87wlww4xu.44q Sign up to see emailv2v5f31@57uuyl00b.1ls Sign up to see email -
gu1k1@48vb83qv9.wk8 Sign up to see email
-
Kelley Dealhoy
Senior Vice President and Chief Business Officer
vutfs6nq@4j1fu3336.0gt Sign up to see email43uu5w7z@vjnfusjf4.t01 Sign up to see email -
Kevin Brodbeck, Ph.D.
Senior Vice President, Chief Technical Officer
0u0863j5j.01.l@fv756s86t.x1l Sign up to see emailq1v3vnz73.w9.6@nt1zsxz6j.476 Sign up to see email -
Lisa Amaya Price
Senior Vice President and Chief Human Resources Officer
1g1vzw.uj78j@wxw8vwq19.8q5 Sign up to see email2fw8n2.309ub@30qnkjv4z.vnz Sign up to see email -
Margarida Duarte
Senior Vice President, Head of International
vbbyg54@0746j88s6.zzy Sign up to see emailqq0x3xw@k8g0kxqxq.j54 Sign up to see email -
Matthew L. Sherman, M.D.
Executive Vice President, Chief Medical Officer
43.bgkyt58.9.8@4wt9418vw.96b Sign up to see email1f.jwu8w9j.2.7@0j0b2tbkw.y2f Sign up to see email -
Rodrigo Ruiz Soto, M.D.
Senior Vice President, Clinical Development
q56g4.00v6.x.4@4q8jlb009.lb1 Sign up to see emailw0970.j3xy.9.y@qwb6jy3xk.xl0 Sign up to see email -
f1.45491v3@q5bfk074u.19z Sign up to see email
-
Tucker Kelly
Executive Vice President, Chief Financial Officer and Treasurer
5b2b8b@qgww5gjvq.f1z Sign up to see emailu68b6v@x7zq2u6vg.w6v Sign up to see email
Deciphera Pharmaceuticals' Mission
Deciphera Pharmaceuticals is dedicated to developing innovative scientific solutions to provide hope to individuals living with cancer. Their mission revolves around improving the quality of life for cancer patients through groundbreaking research and development of new therapies. By focusing on creating advanced treatments, Deciphera aims to address the unmet medical needs in oncology, offering patients and healthcare providers new options in the fight against cancer.
Deciphera Pharmaceuticals' Drug Pipeline
Deciphera Pharmaceuticals boasts a diverse pipeline of drug candidates designed to enhance patients' quality of life. Their proprietary drug discovery platform is pivotal in developing switch-control kinase inhibitors. Among their most notable drugs is QINLOCK (ripretinib), which is already marketed for the treatment of gastrointestinal stromal tumors (GIST). Additionally, the company is conducting clinical studies for several other investigational candidates, including ripretinib, vimseltinib, and DCC-3116, showcasing their commitment to expanding therapeutic options in oncology.
Deciphera Pharmaceuticals' Proprietary Technology
At the heart of Deciphera Pharmaceuticals' innovation is their proprietary drug discovery platform, which focuses on designing switch-control kinase inhibitors. This technology enables the precise targeting of kinases involved in cancer progression, allowing for the development of more effective and selective cancer therapies. The platform’s unique approach to kinase inhibition sets Deciphera apart in the oncology field, underpinning the creation of novel treatments that can significantly improve patient outcomes.
Deciphera Pharmaceuticals' Global Operations
Headquartered in Waltham, MA, Deciphera Pharmaceuticals operates research facilities in Lawrence, KS, and has a significant international presence. The company maintains offices in several European countries, including Switzerland, Germany, France, Italy, and Spain, facilitating global collaboration and distribution of their products. This international footprint enables Deciphera to leverage diverse scientific expertise and bring their innovative treatments to a broader patient population worldwide.
Deciphera Pharmaceuticals' Expanded Access Program (EAP)
Deciphera Pharmaceuticals offers an Expanded Access Program (EAP) to provide investigational medicines to patients under certain conditions. This program reflects the company’s commitment to patient care, allowing those who meet specific criteria access to potentially life-saving treatments before they are commercially available. By offering the EAP, Deciphera ensures that patients in critical need can benefit from their cutting-edge research and development efforts.
Report inaccurate information
Report inaccurate information
